Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro 비교

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	AntibodyLimited DatastalePhase 1 Syngeneic Lymphocytes (CD4+, Syngeneic Lymphocytes, Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro) National Human Genome Research Ins…·Acquired Immunodeficiency Syndrome 124 trials

Overview Program	Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
Overview Company	National Human Genome Research Institute (NHGRI)
Overview Modality	ANTIBODY
Overview Target	Acquired Immunodeficiency Syndrome
Overview Indication	Acquired Immunodeficiency Syndrome; HIV Infection
Overview Phase	PHASE_1
Overview Status	ACTIVE
Overview Content status	Limited Data
Overview Data Confidence	Data Confidence · Low
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

MoA Mechanism	remains poorly understood
MoA Biomarker	PD-1⁺ TIM-3⁺ CD8⁺ and CD4⁺ T cells were analyzed by flow

PK/PD Species	Mouse
PK/PD Animal (cat.)	Mouse
PK/PD Experiment	PD

Toxicology Species	Mouse
Toxicology Animal (cat.)	Mouse
Toxicology Major finding	thrombocytopenia, bone marrow suppression, thymic injury, and prolonged impairment of T-cell rec

Clinical Safety signal	thrombocytopenia, bone marrow suppression, thymic injury, and prolonged impairment of T-cell rec
Clinical Selected reported efficacy	80.3%
Clinical Result source	ClinicalTrials.gov NCT03483103
Clinical Program phase	PHASE_1
Clinical Trial activity	No active/completed counts
Clinical Trial ref	NCT03483103

선택됨 (1/5)

추천 · 인기 프로그램

최대 5개 선택 · 전체 25+ 프로그램은 검색으로 찾을 수 있습니다. ADC 목록 →

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	AntibodyLimited DatastalePhase 1 Syngeneic Lymphocytes (CD4+, Syngeneic Lymphocytes, Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro) National Human Genome Research Ins…·Acquired Immunodeficiency Syndrome 124 trials

Overview Program	Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
Overview Company	National Human Genome Research Institute (NHGRI)
Overview Modality	ANTIBODY
Overview Target	Acquired Immunodeficiency Syndrome
Overview Indication	Acquired Immunodeficiency Syndrome; HIV Infection
Overview Phase	PHASE_1
Overview Status	ACTIVE
Overview Content status	Limited Data
Overview Data Confidence	Data Confidence · Low
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

MoA Mechanism	remains poorly understood
MoA Biomarker	PD-1⁺ TIM-3⁺ CD8⁺ and CD4⁺ T cells were analyzed by flow

PK/PD Species	Mouse
PK/PD Animal (cat.)	Mouse
PK/PD Experiment	PD

Toxicology Species	Mouse
Toxicology Animal (cat.)	Mouse
Toxicology Major finding	thrombocytopenia, bone marrow suppression, thymic injury, and prolonged impairment of T-cell rec

Clinical Safety signal	thrombocytopenia, bone marrow suppression, thymic injury, and prolonged impairment of T-cell rec
Clinical Selected reported efficacy	80.3%
Clinical Result source	ClinicalTrials.gov NCT03483103
Clinical Program phase	PHASE_1
Clinical Trial activity	No active/completed counts
Clinical Trial ref	NCT03483103